PET/CT Imaging in Prostate Cancer Patients

Insights into the Prostate Cancer Imaging Landscape

Video Library —February 15, 2022

Categories:

Interview with the Innovators
Steven Rowe, MD, PhD
Radiology and Radiological Science
Johns Hopkins Medicine,
Baltimore, MD
Dr Steven Rowe shares insights into the prostate cancer imaging landscape and the logistics involved with different radiotracers, with particular emphasis on PYLARIFY® (piflufolastat F 18).
Related Articles
Navigating Patients with Chronic Lymphocytic Leukemia: An interview with Nikki Barkett, BSN, RN, OCN, and Chelsea Passwater, DNP, RN, AGCNS-BC, OCN, of the AONN+ CLL CAPE Initiative
September 2022 Vol 13, No 9
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The American Cancer Society estimates over 20,000 new CLL cases and over 4000 attributed deaths in 2022.
Results from the OSPREY Trial in Pre-Prostatectomy Patients
Steven Rowe, MD, PhD
|
Video Library
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.
PYLARIFY Imaging in High-Risk Prostate Cancer
Steven Rowe, MD, PhD
|
Video Library
Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer.
Last modified: November 15, 2022

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009-2023 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512